Corcept execs enjoy raises in wake of drug OK

The San Francisco Business Times reports that Corcept Therapeutics execs earned 10% salary hikes after last year's approval of the Cushing's syndrome drug Korlym. CEO Joe Belanoff led the pack with an expanded $530,000 salary, up from $481,097. The rare-disease therapy costs up to $20,000 a month. Story

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.